Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 3185232, 11 pages
http://dx.doi.org/10.1155/2016/3185232
Research Article

Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease

1Victor Babes National Institute of Pathology, Biochemistry-Proteomics Department, Splaiul Independentei 99-101, Sector 5, 050096 Bucharest, Romania
2Cellular and Molecular Medicine Department, Carol Davila University of Medicine and Pharmacy, No. 8 B-dul Eroilor Sanitari, Sector 5, 050474 Bucharest, Romania
3Fundeni Clinic of Nephrology, Carol Davila University of Medicine and Pharmacy, Șoseaua Fundeni 258, Sector 2, 022328 Bucharest, Romania
4Fundeni Clinical Institute, Nephrology Department, Șoseaua Fundeni 258, Sector 2, 022328 Bucharest, Romania
5National Institute for Chemical Pharmaceutical R&D, Pharmaceutical Biotechnology Department, Calea Vitan 112, Sector 3, 031299 Bucharest, Romania
6Stefan S. Nicolau Institute of Virology, Molecular Virology Department, Șoseaua Mihai Bravu 285, Sector 3, 030304 Bucharest, Romania
7Faculty of Medicine, Titu Maiorescu University, Strada Dâmbovnicului 22, Sector 4, 040441 Bucharest, Romania

Received 7 April 2016; Accepted 27 July 2016

Academic Editor: Simone Ribero

Copyright © 2016 Simona Mihai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Gluba-Brzózka, M. Michalska-Kasiczak, B. Franczyk et al., “Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study,” Lipids in Health and Disease, vol. 15, no. 1, article 32, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Zoccali, A. Kramer, and K. J. Jager, “Epidemiology of CKD in Europe: an uncertain scenario,” Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1731–1733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Bruck, V. S. Stel, G. Gambaro et al., “CKD prevalence varies across the european general population,” Journal of the American Society of Nephrology, vol. 27, no. 7, pp. 2135–2147, 2016. View at Publisher · View at Google Scholar
  4. A. Gluba-Brzozka, M. Michalska-Kasiczak, B. Franczyk et al., “Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study,” Lipids in Health and Disease, vol. 15, no. 1, p. 22, 2016. View at Publisher · View at Google Scholar
  5. E. Aikawa, M. Aikawa, P. Libby et al., “Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease,” Circulation, vol. 119, no. 13, pp. 1785–1794, 2009. View at Google Scholar
  6. M. L. Ford, E. R. Smith, L. A. Tomlinson, P. K. Chatterjee, C. Rajkumar, and S. G. Holt, “FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart,” Nephrology Dialysis Transplantation, vol. 27, no. 2, pp. 727–733, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Liabeuf, H. Okazaki, L. Desjardins et al., “Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?” Nephrology Dialysis Transplantation, vol. 29, no. 7, pp. 1275–1284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, “KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD),” Kidney International, vol. 76, supplement 113, pp. S1–S130, 2009. View at Google Scholar
  9. D. Brancaccio, M. Gallieni, S. Pasho et al., “Pathogenesis and treatment of vascular calcification in CKD,” Giornale Italiano di Nefrologia, vol. 26, supplement 45, pp. S20–S27, 2009. View at Google Scholar · View at Scopus
  10. G. London, D. Coyne, K. Hruska, H. H. Malluche, and K. J. Martin, “The new kidney disease: Improving global outcomes (KDIGO) guidelines—expert clinical focus on bone and vascular calcification,” Clinical Nephrology, vol. 74, no. 6, pp. 423–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Rogers, C. Goettsch, and E. Aikawa, “Medial and intimal calcification in chronic kidney disease: stressing the contributions,” Journal of the American Heart Association, vol. 2, no. 5, article e000481, 2013. View at Google Scholar · View at Scopus
  12. F. Rutsch, Y. Nitschke, and R. Terkeltaub, “Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel,” Circulation Research, vol. 109, no. 5, pp. 578–592, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Hofmann Bowman and E. M. McNally, “Genetic pathways of vascular calcification,” Trends in Cardiovascular Medicine, vol. 22, no. 4, pp. 93–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. J. O'donnell, M. Kavousi, A. V. Smith et al., “Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction,” Circulation, vol. 124, no. 25, pp. 2855–2864, 2011. View at Publisher · View at Google Scholar
  15. S. Evrard, P. Delanaye, S. Kamel et al., “Vascular calcification: from pathophysiology to biomarkers,” Clinica Chimica Acta, vol. 438, pp. 401–414, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Philippe Rouet, E. Nkuipou-Kenfack, F. Duranton et al., “Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease,” PLoS ONE, vol. 9, no. 5, Article ID e96955, 2014. View at Publisher · View at Google Scholar
  17. M. Breit and K. M. Weinberger, “Metabolic biomarkers for chronic kidney disease,” Archives of Biochemistry and Biophysics, vol. 589, pp. 62–80, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Neagu, “The immune system—a hidden treasure for biomarker discovery in cutaneous melanoma,” Advances in Clinical Chemistry, vol. 58, pp. 89–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. P. Tanase, M. Neagu, and R. Albulescu, “Key signaling molecules in pituitary tumors,” Expert Review of Molecular Diagnostics, vol. 9, no. 8, pp. 859–877, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Mischak, C. Delles, A. Vlahou, and R. Vanholder, “Proteomic biomarkers in kidney disease: issues in development and implementation,” Nature Reviews Nephrology, vol. 11, no. 4, pp. 221–232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. I. D. Popescu, E. Codrici, L. Albulescu et al., “Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches,” Proteome Science, vol. 12, no. 1, article 47, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. J. Pena, D. De Zeeuw, H. Mischak et al., “Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes,” Nephrology Dialysis Transplantation, vol. 30, supplement 4, pp. iv86–iv95, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Bulman, M. Neagu, and C. Constantin, “Immunomics in skin cancer—improvement in diagnosis, prognosis and therapy monitoring,” Current Proteomics, vol. 10, no. 3, pp. 202–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Neagu, C. Constantin, and C. Tanase, “Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma,” Expert Review of Molecular Diagnostics, vol. 10, no. 7, pp. 897–919, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. P. Tanase, R. Albulescu, and M. Neagu, “Application of 3D hydrogel microarrays in molecular diagnostics: advantages and limitations,” Expert Review of Molecular Diagnostics, vol. 11, no. 5, pp. 461–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. C. P. Tanase, M. Neagu, R. Albulescu, E. Codorean, and S. O. Dima, “Biomarkers in the diagnosis and early detection of pancreatic cancer,” Expert Opinion on Medical Diagnostics, vol. 3, no. 5, pp. 533–546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Neagu, C. Constantin, G. Manda, and I. Margaritescu, “Biomarkers of metastatic melanoma,” Biomarkers in Medicine, vol. 3, no. 1, pp. 71–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Neagu, C. Constantin, and S. Zurac, “Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations,” BioMed Research International, vol. 2013, Article ID 107940, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Pistol-Tanase, E. Raducan, S. O. Dima et al., “Assessment of soluble angiogenic markers in pancreatic cancer,” Biomarkers in Medicine, vol. 2, no. 5, pp. 447–455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. C. P. Tanase, A.-M. Enciu, S. Mihai, A. I. Neagu, B. Calenic, and M. L. Cruceru, “Anti-cancer therapies in high grade gliomas,” Current Proteomics, vol. 10, no. 3, pp. 246–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. I. D. Popescu, R. Albulescu, E. Raducan, A. Dinischiotu, and C. Tănase, “Applications of SELDI-TOF technology in cancer biomarkers discovery,” Romanian Biotechnological Letters, vol. 15, no. 5, pp. 5654–5667, 2010. View at Google Scholar
  32. F. M. Shaheen, R. Kurpad, A. Al-Sayyari et al., “Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: the OCEANOS study,” Saudi Journal of Kidney Diseases and Transplantation, vol. 27, no. 2, article 290, 2016. View at Publisher · View at Google Scholar
  33. A. G. Abraham, A. Darilay, H. McKay et al., “Kidney dysfunction and markers of inflammation in the multicenter AIDS cohort study,” The Journal of Infectious Diseases, vol. 212, no. 7, pp. 1100–1110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Hénaut, M. D. Sanchez-Nino, G. Aldamiz-Echevarría Castillo, A. B. Sanz, and A. Ortiz, “Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification,” Expert Opinion on Therapeutic Targets, vol. 20, no. 1, pp. 89–105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Okada, K. Wakai, M. Naito et al., “Pro-/anti-inflammatory cytokine gene polymorphisms and chronic kidney disease: a cross-sectional study,” BMC Nephrology, vol. 13, no. 1, article 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. D. V. Barreto, F. C. Barreto, S. Liabeuf et al., “Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease,” Kidney International, vol. 77, no. 6, pp. 550–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Stenvinkel, M. Ketteler, R. J. Johnson et al., “IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly,” Kidney International, vol. 67, no. 4, pp. 1216–1233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Oh, H. R. Kim, M. K. Lee, and Y. S. Woo, “Profile of human β-defensins 1,2 and proinflammatory cytokines (TNF-α, IL-6) in patients with chronic kidney disease,” Kidney & Blood Pressure Research, vol. 37, no. 6, pp. 602–610, 2013. View at Google Scholar
  39. B. Spoto, D. Leonardis, R. M. Parlongo et al., “Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 11, pp. 981–988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Spoto, F. Mattace-Raso, E. Sijbrands et al., “Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 2, pp. 232–240, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. M. I. Yilmaz, D. Siriopol, M. Saglam et al., “Osteoprotegerin in chronic kidney disease: associations with vascular damage and cardiovascular events,” Calcified Tissue International, vol. 99, no. 2, pp. 121–130, 2016. View at Google Scholar
  42. K. Caidahl, T. Ueland, and P. Aukrust, “Osteoprotegerin: a biomarker with many faces,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1684–1686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Demir, F. Erdenen, H. Aral et al., “Serum osteoprotegerin levels related with cardiovascular risk factors in chronic kidney disease,” Journal of Clinical Laboratory Analysis, 2016. View at Publisher · View at Google Scholar
  44. M. Morena, A.-M. Dupuy, I. Jaussent et al., “A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients,” Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3389–3397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Mesquita, A. Demulder, F. Wolff et al., “Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease,” Transplantation Proceedings, vol. 42, no. 9, pp. 3444–3449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. J. R. Lewis, W. H. Lim, T. Ueland et al., “Elevated circulating osteoprotegerin and renal dysfunction predict 15-year cardiovascular and all-cause mortality: a prospective study of elderly women,” PLoS ONE, vol. 10, no. 7, Article ID e0134266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. G. M. London, “Bone-vascular axis in chronic kidney disease: a reality?” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 254–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. N. K. Lee, H. Sowa, E. Hinoi et al., “Endocrine regulation of energy metabolism by the skeleton,” Cell, vol. 130, no. 3, pp. 456–469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. A. N. Kapustin and C. M. Shanahan, “Osteocalcin: a novel vascular metabolic and osteoinductive factor?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 10, pp. 2169–2171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Eleftheriadis, C. Kartsios, G. Antoniadi et al., “The impact of chronic inflammation on bone turnover in hemodialysis patients,” Renal Failure, vol. 30, no. 4, pp. 431–437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. D. V. Barreto, A. Lenglet, S. Liabeuf et al., “Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease,” Nephron Clinical Practice, vol. 117, no. 4, pp. c363–c372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. J. M. Lorenzen, H. Neunhöffer, S. David, J. T. Kielstein, H. Haller, and D. Fliser, “Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension—results from the EUTOPIA trial,” Atherosclerosis, vol. 209, no. 1, pp. 184–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Evenepoel, B. Meijers, L. Viaene et al., “Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1268–1276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Yasin, D. Liu, L. Chau, J. Madrenas, and G. Filler, “Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study,” BMC Nephrology, vol. 14, no. 1, article 39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. J. J. Scialla, H. Xie, M. Rahman et al., “Fibroblast growth factor-23 and cardiovascular events in CKD,” Journal of the American Society of Nephrology, vol. 25, no. 2, pp. 349–360, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Chudek, P. Kocełak, A. Owczarek et al., “Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly,” Nephrology Dialysis Transplantation, vol. 29, no. 9, pp. 1757–1763, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Stompór, “Coronary artery calcification in chronic kidney disease: an update,” World Journal of Cardiology, vol. 6, no. 4, p. 115, 2014. View at Publisher · View at Google Scholar
  58. M. Wolf, “Update on fibroblast growth factor 23 in chronic kidney disease,” Kidney International, vol. 82, no. 7, pp. 737–747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. V. David, A. Martin, T. Isakova et al., “Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production,” Kidney International, vol. 89, no. 1, pp. 135–146, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Desjardins, S. Liabeuf, C. Renard et al., “FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages,” Osteoporosis International, vol. 23, no. 7, pp. 2017–2025, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. N. X. Chen and S. M. Moe, “Pathophysiology of vascular calcification,” Current Osteoporosis Reports, vol. 13, no. 6, pp. 372–380, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. E. R. Smith, M. L. Ford, L. A. Tomlinson et al., “Serum calcification propensity predicts all-cause mortality in predialysis CKD,” Journal of the American Society of Nephrology, vol. 25, no. 2, pp. 339–348, 2014. View at Publisher · View at Google Scholar · View at Scopus